Article Figures & Data
Figures
- Figure 1.
Comparison of baseline CAF levels in patients with and without PD for the eight high-risk markers. NED, no evidence of disease.
- Figure 2.
Elevations in ≥6 of 8 high-risk CAFs is associated with PD. The number of high-risk CAFs (VEGF, IL-4, IL-8, Gro-α, SDF-1α, G-CSF, osteopontin, and eotaxin) above the median was plotted for each patient (A). HPV status is indicated by open (HPV-positive) and closed symbols (HPV-negative). Patients with PD are indicated in red. Kaplan-Meier curve is shown for time to progression in patients with 0 to 5 versus 6 to 8 high-risk CAFs above the median (B). PFS, progression-free survival.
- Figure 3.
Unsupervised clustering identified two distinct subgroups that correlate with clinical outcome but not with HPV status. Relative serum levels of 38 baseline CAFs are shown (red, high protein levels; green, low protein levels). Each row contains CAF levels for an individual patient. Two distinct patient CAF profiles are identified (clusters 1 and 2), and all six patients with PD are in cluster 2, which is characterized by higher levels of hypoxia-associated factors, as indicated in the figure. There is no association between HPV status and clusters. See Table 1 legend for definitions of abbreviations.
Tables
- Table 1.
Cytokines and angiogenic factors in serum biomarker analysis
βNGF IL-18 MIF CTACK IL-1RA MIG Eotaxin IL-2 MIP-1β G-CSF IL-2RA Osteopontin GRO-α IL-3 PDGF-bb HGF IL-4 RANTES ICAM-1 IL-6 SCF IFN-α2 IL-7 SDF-1α IFN-γ IL-8 TNF-β IGF-I IP-10 TRAIL IL-12(p40) MCP-1 VCAM-1 IL-13 MCP-3 VEGF IL-16 M-CSF Abbreviations: CTACK, cutaneous T cell-attracting chemokine; G-CSF, granulocyte colony stimulating factor; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; ICAM, intercellular adhesion molecule; IFN, interferon; MIP, macrophage inflammatory protein; MIF, macrophage migration inhibitory factor; MCP, monocyte chemotactic protein; M-CSF, monocyte colony stimulating factor; MIG, monokine induced by IFN-γ; NGF, nerve growth factor; PDGF, platelet-derived growth factor; RANTES, regulated upon activation, normal T-cell expressed and secreted; SCF, stem cell factor; TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis inducing ligand; VCAM, vascular cell adhesion molecule.
- Table 2.
Clinicopathologic characteristics in patients with progression
PD P No (n = 26) Yes (n = 6) Age, median (range) 52 (21–76) 59 (52–71) 0.049* Sex Male 18 (90%) 2 (10%) 0.17 Female 8 (66.7%) 4 (33.3%) — Race White 24 (82.8%) 5 (17.2%) 0.48 Black 0 (0%) 1 (100%) — Hispanic 1 (100%) 0 (0%) — Asian 1 (100%) 0 (0%) — Smoking status Never smoker 12 (92.3%) 1 (7.7%) 0.17 Former smoker 8 (88.9%) 1 (11.1%) — Current smoker 6 (60%) 4 (40%) — Differentiation Well 1 (100%) 0 (0%) 0.70 Moderate 7 (87.5%) 1 (12.5%) — Poorly 11 (84.6%) 2 (15.4%) — Moderately well 1 (50%) 1 (50%) — Poorly moderately 2 (100%) 0 (0%) — T stage T1–T2 18 (86%) 3 (14%) 0.003 T3–T4 8 (73%) 3 (27%) — N stage N2B 19 (90.5%) 2 (9.5%) 0.090 N2C 5 (62.5%) 3 (37.5%) — N3 1 (50%) 1 (50%) — EGFR† 0 0 (0%) 0 (0%) 0.78 1+ 4 (100%) 0 (0%) 2+ 5 (100%) 0 (0%) 3+ 37 (82.2%) 8 (17.8%) HPV‡ HPV positive 12 (100%) 0 (0%) 0.008 HPV negative 8 (57%) 6 (43%) - Table 3.
Baseline CAFs associated with PD
Covariate Progression n Mean ± SD* Median (min, max)* P† Eotaxin Yes 6 4.8 ± 0.6 5.1 (4.1, 5.4) 0.016 No 26 2.6 ± 2.0 2.6 (0, 5.9) Osteopontin Yes 6 4.0 ± 2.1 4.5 (0, 6.2) 0.021 No 26 2.0 ± 1.8 2.3 (0, 5.3) G-CSF Yes 6 6.4 ± 1.5 5.9 (5.3, 9.2) 0.039 No 26 4.2 ± 2.1 3.6 (2.3, 9.8) IL-4 Yes 6 2.7 ± 0.6 2.8 (1.9, 3.6) 0.040 No 26 1.8 ± 0.9 1.7 (0.4, 3.4) SDF-1α Yes 6 8.6 ± 0.2 8.6 (8.4, 8.9) 0.044 No 26 8.0 ± 0.9 8.0 (6.5, 9.9) VEGF Yes 6 6.0 ± 2.1 6.3 (3.7, 9.1) 0.049 No 26 3.6 ± 2.5 3.2 (0.1, 8.3) GRO-α Yes 6 7.1 ± 0.7 6.9 (6.2, 8.2) 0.049 No 26 6.3 ± 0.7 6.3 (4.5, 7.9) — IL-8 Yes 6 5.5 ± 2.5 4.6 (3.2, 10) 0.050 No 26 2.9 ± 2.6 2.4 (0.5, 9.1)
Volume 9, Issue 6
